Allergen immunotherapy

Mayo Clinic Proceedings

Volumn 82, Issue 9, 2007, Pages 1119-1123

  Rank, Matthew A ^a   Li, James T C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALLERGEN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CORTICOSTEROID; IMMUNOLOGICAL ADJUVANT; OMALIZUMAB; PEPTIDE; PLACEBO; RECOMBINANT VACCINE; VENOM;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC REACTION; ALLERGY; ALLERGY TEST; ANAPHYLAXIS; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INSECT ALLERGY; MAINTENANCE THERAPY; PATIENT SELECTION; REVIEW; RHINOCONJUNCTIVITIS; TREATMENT DURATION; TREATMENT INDICATION;

EID: 34548427766     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.9.1119     Document Type: Review

References (43)

1. Bellanti JA, Wallerstedt DB. Allergic rhinitis update: epidemiology and natural history. Allergy Asthma Proc. 2000;21(6):367-370.
2. Law AW, Reed SD, Sundy JS, Schulman KA. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol. 2003;111(2):296-300.
3. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med. 2004;46(4):398-412.
4. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma - United States, 1980-1999. MMWR Surveill Summ. 2002;51(1):1-13.
5. Eder W, Ege MJ, and von Mutius E. The asthma epidemic. N Engl J Med. 2006;355(21):2226-2235.
6. Barnard JH. Studies of 400 hymenoptera sting deaths in the United States. J Allergy Clin Immunol. 1973;52(5):259-264.
7. Moffitt JE, Golden DBK, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol. 2004;114(4):869- 886.
8. Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;177(4580):1572-1573.
9. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet. 1911;178(4594):814- 817.
10. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113(6):1025-1034.
11. White P, Smith H, Webley F, Frew A. A survey of the quality of information leaflets on hayfever available from general practices and community pharmacies. Clin Exp Allergy. 2004;34(9):1438-1443.
12. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin Ther. 2000;22(3): 342-350.
13. Frew AJ, Powell RJ, Corrigan CJ, Durham SR, for the UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(2):319-325.
14. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468-475.
15. Pajno GB, Barberio G, De Luca F, Moribito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy. 2001;31(9):1392-1397.
16. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, IV: specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99(4):450-453.
17. Purello-D'Ambrosio F, Gangemi S, Merendino R, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not: a retrospective study. Clin Exp Allergy. 2001;31(8):1295-1302.
18. Niggemann B, Jacobsen L, Dreborg S, et al, PAT Investigator Group. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855-859.
19. Valovirta E, Jacobsen L, Niggemann B, et al. A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children: ten year follow-up on the PAT-study. J Allergy Clin Immunol. 2006;117(3):721.
20. Ross RN, Nelson HS, Finegold I. Effectiveness of immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther. 2000;22(3):329-341.
21. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;(4):CD001186.
22. Shaikh WA. Immunotherapy vs inhaled budesonide in bronchial asthma: an open, parallel, comparative trial. Clin Exp Allergy. 1997;27(11):1279- 1284.
23. Freeman TM. Hypersensitivity to hymenoptera stings. N Engl J Med. 2004;351(19):1978-1984.
24. Golden DB, Tracy JM, Freeman TM, Hoffman DR, Insect Committee of the American Academy of Allergy, Asthma and Immunology. Negative venom skin test results in patients with histories of systemic reaction to a sting. J Allergy Clin Immunol. 2003;112(3):495-498.
25. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978;299(4):157-161.
26. Muller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity: bee venom versus wholebody extract. Allergy. 1979;34(6):369-378.
27. Golden DBK, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med. 2004;351(7):668-674.
28. Golden DBK. Insect sting allergy and venom immunotherapy. Ann Allergy Asthma Immunol. 2006;96(suppl 1):S16-S21.
29. Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee of the American Academy of Allergy, Asthma and immunology, Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004;113(6):1129-1136.
30. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006;117(1):169-175.
31. Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116(1):109-118.
32. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006;97(2):126-137.
33. Joint Task Force on Practice Parameters. Allergen immunotherapy: a practice parameter. Ann Allergy Asthma Immunol. 2003;90(1, suppl 1):1-40.
34. Joint Task Force on Practice Parameters. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115(3, suppl 2):S483-S523.
35. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systemic review and meta-analysis. Allergy. 2005:60(1):4-12.
36. Rolinck-Werninghaus C, Hamlemann E, Keil T, et al, Omalizumab Rhinitis Study Group. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004;59(9):973-979.
37. Casale TB, Busse WW, Kline JN, et al, Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006 Jan;117(1):134-140. Epub 2005 Dec 2.
38. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274-280.
39. US Food and Drug Administration. FDA proposes to strengthen label warning for Xolair. Available at: www.fda.gov/bbs/topics/NEWS/2007/NEW01567.html. Accessed May 23, 2007.
40. Creticos PS, Schroeder JT, Hamilton PG, et al, Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355(14):1445-1455.
41. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005 Nov; 116(5):1073-1079. Epub 2005 Oct 3.
42. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006;61(7):202-205.
43. Global strategy for asthma management and prevention, Global Initiative for Asthma (GINA) 2006. Available at: www.ginasthma.org/Guidelineitem.asp??11= 2&12=1&intId=60. Accessed May 23, 2007.